content: SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, DC  20549
  
                                   ________________
  
                                       FORM 8-K
  
                                    CURRENT REPORT
                          PURSUANT TO SECTION 13 OR 15(D) OF
                          THE SECURITIES EXCHANGE ACT OF 1934
  
  
          Date of report (Date of earliest event reported)  June 10, 1999
  
  
                                         SCIOS INC.
                     (Exact Name of Registrant as Specified in Charter)
  
  
  
           Delaware                   0-11749                   95-3701481
  (State of Other Jurisdiction      (Commission               (IRS Employer
          of Incorporation)         File Number)            Identification No.)
  
  
  
              2450 Bayshore Parkway, Mountain View, California  94043
                       (Address of Principal Executive Offices)
  
  
  
         Registrant's telephone number, including area code  (650) 966-1550
  
  
  
  
  
  
  
  
  
  
  
  Item 5.  Other Events
  
           On June 9, 1999, Scios Inc. announced that the May 11, 1998 commercial
  alliance with Bayer Corporation regarding Natrecor(R) (nesiritide) was
  terminated.
  
  
  Exhibits.
  
           99.1     Press Release dated June 9, 1999
  
  
  
           Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.
  
                                                       SCIOS INC.
  
  
  Date:  June 10, 1999                          By:
                                                         David S. Gryska
                                                         Chief Financial Officer
  
  
  
                                  INDEX TO EXHIBITS
  
                                      SCIOS INC.
  
                       Report on Form 8-K dated June 10, 1999
  
  
  
  
  Exhibit     Description                           Method of Filing
  
  99.1        Press Release dated June 9, 1999      Filed electronically herewith
  
  
                                                               Exhibit 99.1
  
  
  
  
  
  
  
  
  
  
     SCIOS AND BAYER DISSOLVE COMMERCIAL ALLIANCE REGARDING NATRECOR(R) IN
                     ACUTE CONGESTIVE HEART FAILURE
  
  -Scios designing new clinical trial while reviewing new partner opportunities-
  
  
  MOUNTAIN VIEW, Calif. - June 9, 1999 - Scios Inc. (NASDAQ: SCIO) today announced
  that  the  commercial  alliance  with  Bayer  Corporation,  formed  in May  1998
  regarding  Natrecor(R)  (nesiritide) in acute congestive heart failure, has been
  dissolved.  Scios recently received notice from the Food and Drug Administration
  (FDA) that Natrecor  would need to  successfully  complete  additional  clinical
  study to gain approval.
  
  "Bayer decided to reassess the basis of its continued commercial alliance with
  Scios regarding Natrecor after the FDA non-approvable letter on the Natrecor
  new drug application," said Richard B. Brewer, President and CEO of Scios Inc.
  "Agreement could not be reached on a new commercial alliance."
  
  With the  dissolution  of the alliance  with Bayer  Corporation,  all rights and
  responsibilities for Natrecor development and commercialization revert to Scios.
  As a result the company is reviewing new partner  opportunities.  The company is
  now directing its full  attention to designing an additional  clinical  trial to
  meet the FDA's  concerns  expressed in the April,  1999 Natrecor  non-approvable
  letter.  Scios is  collaborating  with outside  experts in the congestive  heart
  failure  community in the design of the next clinical study. In addition,  Scios
  will work in close  collaboration  with the FDA.  The full  details of the trial
  will probably not be available until  mid-summer  (i.e.  trial  enrollment size,
  length of study, and cost).
  
  Scios Inc.
  Scios is a  biopharmaceutical  company  engaged in the  discovery,  development,
  manufacture  and  commercialization  of  novel  human  therapeutics.  Scios  has
  research and development  collaborations  with  Wyeth-Ayerst  Laboratories,  the
  pharmaceutical   division  of  American   Home   Products   Corporation,   Kaken
  Pharmaceutical  Co.,  Ltd.,  Eli Lilly and  Company,  The DuPont Pharmaceuticals
  Company and Novo Nordisk A/S of Denmark.  Scios' commercial  operations division
  successfully markets six psychiatric products.  Additional  information on Scios
  is  available  at its web site  located  at  http://www.sciosinc.com  and in the
  Company's various fillings with the Securities and Exchange Commission.
  
  The  statements  in this  press  release  that  are  not  historical  facts  are
  forward-looking statements that involve risks and uncertainties, and may include
  references to the continued  development and  commercialization of Natrecor,  as
  well as other risks  detailed  from time to time in the  reports  filed by Scios
  with the SEC,  including  annual reports on Form 10K for the year ended December
  31, 1998 and subsequent reports on Form 10Q.
                                                                   # # #
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "8-K", "secsgml_size_bytes": 5061}]
metadata_filer: {"company-data": {"conformed-name": "SCIOS INC", "cik": "0000726512", "assigned-sic": "2834", "irs-number": "953701481", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11749", "film-number": "99644321"}, "business-address": {"street1": "2450 BAYSHORE PKWY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043", "phone": "4159661550"}, "mail-address": {"street1": "2450 BAYSHORE PARKWAY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043"}, "former-company": [{"former-conformed-name": "SCIOS INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA BIOTECHNOLOGY INC", "date-changed": "19920302"}]}
text: SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, DC  20549
  
                                   ________________
  
                                       FORM 8-K
  
                                    CURRENT REPORT
                          PURSUANT TO SECTION 13 OR 15(D) OF
                          THE SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported)  June 10, 1999
  
                                         SCIOS INC.
                     (Exact Name of Registrant as Specified in Charter)
  
           Delaware                   0-11749                   95-3701481
  (State of Other Jurisdiction      (Commission               (IRS Employer
          of Incorporation)         File Number)            Identification No.)
  
              2450 Bayshore Parkway, Mountain View, California  94043
                       (Address of Principal Executive Offices)
  
         Registrant's telephone number, including area code  (650) 966-1550
  
  Item 5.  Other Events
  
           On June 9, 1999, Scios Inc. announced that the May 11, 1998 commercial
  alliance with Bayer Corporation regarding Natrecor(R) (nesiritide) was
  terminated.
  
  Exhibits.
  
           99.1     Press Release dated June 9, 1999
  
           Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.
  
                                                       SCIOS INC.
  
  Date:  June 10, 1999                          By:
                                                         David S. Gryska
                                                         Chief Financial Officer
  
                                  INDEX TO EXHIBITS
  
                                      SCIOS INC.
  
                       Report on Form 8-K dated June 10, 1999
  
  Exhibit     Description                           Method of Filing
  
  99.1        Press Release dated June 9, 1999      Filed electronically herewith
  
                                                               Exhibit 99.1
  
     SCIOS AND BAYER DISSOLVE COMMERCIAL ALLIANCE REGARDING NATRECOR(R) IN
                     ACUTE CONGESTIVE HEART FAILURE
  
  -Scios designing new clinical trial while reviewing new partner opportunities-
  
  MOUNTAIN VIEW, Calif. - June 9, 1999 - Scios Inc. (NASDAQ: SCIO) today announced
  that  the  commercial  alliance  with  Bayer  Corporation,  formed  in May  1998
  regarding  Natrecor(R)  (nesiritide) in acute congestive heart failure, has been
  dissolved.  Scios recently received notice from the Food and Drug Administration
  (FDA) that Natrecor  would need to  successfully  complete  additional  clinical
  study to gain approval.
  
  "Bayer decided to reassess the basis of its continued commercial alliance with
  Scios regarding Natrecor after the FDA non-approvable letter on the Natrecor
  new drug application," said Richard B. Brewer, President and CEO of Scios Inc.
  "Agreement could not be reached on a new commercial alliance."
  
  With the  dissolution  of the alliance  with Bayer  Corporation,  all rights and
  responsibilities for Natrecor development and commercialization revert to Scios.
  As a result the company is reviewing new partner  opportunities.  The company is
  now directing its full  attention to designing an additional  clinical  trial to
  meet the FDA's  concerns  expressed in the April,  1999 Natrecor  non-approvable
  letter.  Scios is  collaborating  with outside  experts in the congestive  heart
  failure  community in the design of the next clinical study. In addition,  Scios
  will work in close  collaboration  with the FDA.  The full  details of the trial
  will probably not be available until  mid-summer  (i.e.  trial  enrollment size,
  length of study, and cost).
  
  Scios Inc.
  Scios is a  biopharmaceutical  company  engaged in the  discovery,  development,
  manufacture  and  commercialization  of  novel  human  therapeutics.  Scios  has
  research and development  collaborations  with  Wyeth-Ayerst  Laboratories,  the
  pharmaceutical   division  of  American   Home   Products   Corporation,   Kaken
  Pharmaceutical  Co.,  Ltd.,  Eli Lilly and  Company,  The DuPont Pharmaceuticals
  Company and Novo Nordisk A/S of Denmark.  Scios' commercial  operations division
  successfully markets six psychiatric products.  Additional  information on Scios
  is  available  at its web site  located  at  http://www.sciosinc.com  and in the
  Company's various fillings with the Securities and Exchange Commission.
  
  The  statements  in this  press  release  that  are  not  historical  facts  are
  forward-looking statements that involve risks and uncertainties, and may include
  references to the continued  development and  commercialization of Natrecor,  as
  well as other risks  detailed  from time to time in the  reports  filed by Scios
  with the SEC,  including  annual reports on Form 10K for the year ended December
  31, 1998 and subsequent reports on Form 10Q.
                                                                   # # #